Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence invited Eli Lilly and Company Ltd, the company manufacturing ixekizumab (tradename Taltz(®)), to submit evidence for the clinical and cost effectiveness of ixekizumab. Ixekizumab was compared with tumour necrosis factor-α inhibitors (etanercept,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramaekers, Bram L. T., Wolff, Robert F., Pouwels, Xavier, Oosterhoff, Marije, Van Giessen, Anoukh, Worthy, Gill, Noake, Caro, Armstrong, Nigel, Kleijnen, Jos, Joore, Manuela A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021474/
https://www.ncbi.nlm.nih.gov/pubmed/29480455
http://dx.doi.org/10.1007/s40273-018-0629-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021474/
https://www.ncbi.nlm.nih.gov/pubmed/29480455
http://dx.doi.org/10.1007/s40273-018-0629-2

Ejemplares similares